

## Title

# Ovarian Cancer Treatments

---

Reference Number: RDF1525-23

Date of Response: 20/06/2023

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

Please be aware that the Royal Devon University Healthcare NHS Foundation Trust (Royal Devon) has existed since 1<sup>st</sup> April 2022 following the integration of the Northern Devon Healthcare NHS Trust (known as Northern Services) and the Royal Devon and Exeter NHS Foundation Trust (known as Eastern Services).

Q1. How many patients have been treated for advanced (FIGO Stages III and IV) ovarian (epithelial ovarian, fallopian tube or primary peritoneal) cancer over the last 3 months? If none, do you refer advanced ovarian cancer patients to another trust, and if so which one?

	Trust Total
FIGO Stage III	47
FIGO Stage IV	14

Q2. How many ovarian cancer patients (any stage) have been treated in the last 3 months with:

- Paclitaxel in combination with a platinum-based compound
- Platinum-based therapy alone (cisplatin or carboplatin)
- Bevacizumab in combination with paclitaxel and carboplatin
- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Rucaparib

	Trust total
Paclitaxel in combination with a platinum-based compound	35
Platinum-based therapy alone (cisplatin or carboplatin)	7
Bevacizumab in combination with paclitaxel and carboplatin	21
Olaparib	*5
Olaparib + Bevacizumab	<5
Niraparib	14
Rucaparib	0

Q3. Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part.

ICON 8	18
IIA-HGSOC	16
Protector	20
Mirasol	* <5

**\* <5 - Section 40 (2) - Less than five**

In accordance with Section 40 (2) of the Freedom of Information Act 2000, we are unable to provide figures where the number of patients/staff is less than or equal to five and could risk the identification of those patients/staff and breach Caldicott principles. In these cases ≤5 is used to indicate that a figure between 1 and 5 is being suppressed.

Please note that if only one cell required suppression, at least one other number has been suppressed to avoid calculation of suppressed values from the totals. (if information presented in table format with totals)

These figures are withheld under Section 40(2) due to low staff numbers. The disclosure of which could risk the identification of those staff members and breach Caldicott principles.

This follows NHS Digital (formerly HSCIC) analysis guidance (2014) which states that small numbers within local authorities, wards, postcode districts, CCG's providers and Trusts may allow identification of patients/staff and should not be published.

Q4. If data for HRD (homologous recombination deficiency) testing is available, please provide how many HRD positive patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatments

Q5. If data for HRD (homologous recombination deficiency) and BRCA testing is available, please provide how many HRD positive BRCA mutated patients were treated in the last 3 months with:

- Olaparib
- Olaparib + Bevacizumab
- Niraparib
- Other treatment

\*\* NB – Q4 & Q5: The Trust applies a refusal notice under Section 17 of the Freedom of Information Act to questions 4 and 5. By applying Section 17, the trust applies the following Exemption:

Section 12 (1) – Time/Cost (over 18hrs work)

HRD and BRCA testing occurs at other Trusts. Results from these tests are subsequently included on patient's Histology reports as an addendum. As no active COSD (Cancer Outcomes and Services Dataset) currently exists on the in-house

patient system Epic, we would be required to manually review each instance of histology reports where a patient has an active stage 3 or 4 ovarian cancer diagnosis (over 100> such cases), before validating with the Cancer Audit Facilitators.

Consequently, when factored in with the time already taken to complete Q1, Q2 and Q3 of this FOI, and the potential combined work involved between BI and CAF, this would take us beyond the 18hr threshold for FOI. To carry out this work would exceed the appropriate cost limit as set out in Section 12 (1) of the Freedom of Information Act 2000 and is therefore exempt.

Under the Freedom of Information Act 2000 Section 12 (1) and defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, a public authority is not obliged to comply with a request for information if it estimates that the cost of complying would exceed the appropriate limit. The limit of £450 represents the estimated cost of one person spending two and a half days in determining whether the Trust holds the information, locating, retrieving and extracting that information.